Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket was written by Sun, Yanying;Kang, Dongwei;Da, Feng;Zhang, Tao;Li, Pei;Zhang, Baodan;De Clercq, Erik;Pannecouque, Christophe;Zhan, Peng;Liu, Xinyong. And the article was included in European Journal of Medicinal Chemistry in 2021.Application In Synthesis of tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate This article mentions the following:
With our previously identified potent NNRTIs 25a and HBS-11c as leads, series of novel thiophene[3,2-d]pyrimidine and thiophene[2,3-d]pyrimidine derivatives were designed via mol. hybridization strategy. All the target compounds were evaluated for their anti-HIV-1 activity and cytotoxicity in MT-4 cells. Compounds 16a1 and 16b1 turned out to be the most potent inhibitors against WT and mutant HIV-1 strains (L100I, K103N, and E138K), with EC50 values ranging from 0.007μM to 0.043μM. Gratifyingly, 16b1 exhibited significantly reduced cytotoxicity (CC50 > 217.5μM) and improved water solubility (S = 49.3μg/mL at pH 7.0) compared to the lead 25a (S < 1μg/mL at pH 7.0, CC50 = 2.30μM). Moreover, mol. docking was also conducted to rationalize the structure-activity relationships of these novel derivatives and to understand their key interactions with the binding pocket. In the experiment, the researchers used many compounds, for example, tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate (cas: 304897-49-2Application In Synthesis of tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate).
tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate (cas: 304897-49-2) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Application In Synthesis of tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics